New drug combo shows promise for deeper remission in chronic leukemia

Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.

Arcadia: Transforming Healthcare with Data-Driven Solutions

What You Should Know: – Arcadia® (arcadia.io), a leading data platform for healthcare, today announced the launch of two new solutions—Enhanced Benchmarks and Arcadia Vista Push—designed

November 14, 2024

Scientists unravel the physics behind belly flops

Anyone who’s ever done a belly flop into a swimming pool knows it ends with a blunt-sounding splat, a big splash and a searing red

November 7, 2023

Tranexamic acid use linked to decreased incidence of heterotopic ossification after elbow trauma surgery

For patients undergoing surgery for elbow trauma, treatment with the hemostatic drug tranexamic acid (TXA) is associated with a decreased incidence of heterotopic ossification (HO)

June 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.